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The ribonuclease H (RNase H) domain of human immuno-deficiency virus (HIV-l) reverse transcriptase has been produced with the aim of provid- 
ing sufficient amounts of protein for biophysical studies. A plasmid vector is described which directs high level expression of the RNase H domain 
under the control of the I PL promoter. The domain corresponds to residues 427-560 of the 66 kDa reverse transcriptase. The protein was expressed 
in Escherichia cob’ and was purified using ion-exchange and size exclusion chromatography. The purified protein appears to be in a native-like 
homogeneous conformational state as determined by iH-NMR spectroscopy and circular dichroism measurements. HIV-protease treatment of the 
RNase H domain resulted in cleavage between Phe-440 and Tyr-441. 
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1. INTRODUCTION 
Ribonuclease H (RNase H) activity resides in the C- 
terminal region of retroviral polymerases as shown by 
deletion experiments [11, linker insertion [2] and point 
mutagenesis [3,4]. The enzyme functions by cleaving 
the RNA portion of a DNA/RNA hybrid, a process 
which is required at several stages during reverse 
transcription of the viral genome within the host cell. 
Recent studies have established that the retroviral 
RNase H displays both endonuclease and 3 ’ -5 ’ ex- 
onuclease activity [5,6]. This activity is crucial for viral 
replication as mutant provirus, defective for RNase H 
function, fails to produce infectious virus particles 
[4,71. Comparisons between retroviral reverse 
transcriptases and other known protein sequences 
revealed significant sequence similarity to E. coli RNase 
H [8], suggesting that the RNase H domain of reverse 
transcriptase and E. coli RNase H may have related 
three-dimensional structures. 
Although recombinant HIV-reverse transcriptase of 
sufficient purity and abundance is available, high 
resolution structural studies have been prevented by the 
lack of crystals suitable for X-ray diffraction analysis. 
The crystals presently available are insufficiently 
ordered to allow a structure determination [9]. To study 
structure-function relationships of the RNase H portion 
of this protein, we have expressed the former in E. coli 
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as a separate 15 kDa protein. The purified protein ap- 
pears suitable for structural studies by both NMR spec- 
troscopy and X-ray analysis, thereby providing an addi- 
tional target in the search for therapeutic agents against 
the spread of HIV infection. 
2. MATERIALS AND METHODS 
2.1. Plasmid construction 
The coding sequence of the RNase H domain was derived from 
M13-RT (Becerra et al., submitted for publication), a subclone of the 
reverse transcriptase gene from HIV-l strain HXB2, inserted between 
the EcoRI and Hind111 cleavaged sites of M13mp18. The RNase H 
coding region is located on a 423 base-pair Asp718 - Hind111 frag- 
ment, corresponding to nucleotides 3406-3809 of the HIV-l sequence 
[lo]. After removal of the internal Asp-718 site (an isoschizomer of 
KpnI) by primer-directed mutagenesis changing the codon for Val-536 
from GTA to GTT, the double-stranded RF form of this DNA was 
cleaved with Asp-718, the 5’ overhang was filled in with the Klenow 
fragment of DNA polymerase 1, and cut with HindIII. The resulting 
DNA fragment containing the coding region for the RNase H domain 
of reverse transcriptase was ligated to pEV-vrfl [ll], an ATG- 
containing expression vector that had been previously digested with 
EcoRI (the 5 ’ overhang filled in with Klenow DNA polymerase) and 
HindIII. This ligation mixture was used to transform E. coli strain 
RR1 [pRK248cIts]. The final construct ~350-13 codes for the se- 
quence Met-Asn-Glu-Leu followed by amino acids 427-560 of reverse 
transcriptase under control of the X PL promoter. 
2.2. Protein expression and fermentation 
Plasmid bearing E. coli was grown in a 2.5 liter fermenter. Culture 
media and fermentation conditions were essentially as described 
previously [12]. When cultures had reached an absorbance of about 
10 at 650 nm, the temperature was raised to 42°C. After 3 h at 42°C 
the cells were harvested to yield about 30 mg (wet weight cells) per ml 
of culture. Harvested cells were stored at - 80°C prior to use. 
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2.3. Purification of HIV - RNase H 
Buffers used in protein purification were: buffer A, 50 mM 
Tris/HCl, pH 8.0; buffer B, 20 mM sodium acetate, pH 4.9; buffer 
C, 50 mM sodium phosphate, pH 7.6. All buffers contained 1 mM 
sodium azide. Cells (60 g wet weight) were resuspended in 170 ml of 
Buffer A and broken by passage through a French pressure cell at 124 
mPa (18,000 Ibf/in’). The suspension was sonicated briefly to reduce 
the viscosity, diluted to a final volume of 300 ml with buffer A and 
centrifuged at 10 000 x g for 45 min. The supernatant was recen- 
trifuged at 100 000 x g for 1 h, then applied at 200 ml/h to a DEAE- 
Sepharose column (5 cm diameter x 20 cm) equilibrated with buffer 
A. A 1 liter linear gradient (O-O.35 M) of NaCl in buffer A was ap- 
plied. HIV-RNase H was eluted with about 50-100 mM NaCl, pooled 
fractions (170 ml) were dialyzed against hree changes of 4 liter buffer 
B. The slightly cloudy solution (180 ml) was clarified by centrifuga- 
tion at 5000 x g for 30 min and the supernatant applied to a CM- 
Sepharose column (5 cm diameter x 15 cm) equilibrated with buffer 
B. A 1 liter gradient (O-O.35 M) of NaCl was applied. A major peak 
of HIV-RNase was eluted with about 200 mM NaCl. In addition a 
minor peak of protein (10% of major peak) was eluted with about 150 
mM NaCl. Both peaks were processed separately. Pooled fractions 
were adjusted to pH 7.5 with 1 M Tris base and concentrated to 15-20 
ml by ultrafiltration using Diaflo YM5 membranes (Amicon) and ap- 
plied at 40 ml/h to a column (2.5 cm diameter x 95 cm) of Spec- 
tra/Gel AcA 54 (Spectrum/Medical Industries, Inc.) equilibrated 
with buffer C. Fractions containing HIV-RNase H were pooled, con- 
centrated by ultrafiltration to 10 mg/ml, sterile filtered using 0.22 pm 
pore size Millex GV filter units (Millipore) and stored at - 80°C. 
2.4. Protein estimations 
Protein concentration was estimated by measuring the absorbance 
at 280 nm. The calculated molar absorbance coefficient (E) used was 
13.50 mM cm-’ (based on a molecular mass of 15,200). 
2.5. Enzymic assay 
The substrate for the assay, [32P]bx174 DNA-RNA hydrid, was 
prepared as described previously [13] using @P]UTP as the label. 
The assay buffer was 50 mM Tris/HCl, 50 mM NaCl, 5 mM MgClz, 
0.1 mM DTT, pH 7.9 and the substrate concentration about 0.5 
gg/ml. Purified HIV-1 RNase H domain was incubated at 37°C with 
(b) 
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Fig. 1. (a) Expression plasmid for HIV-l RNase H. The asterisk (*) 
refers to nucleotide 3407 of the HIV-l gene sequence [lo] and is the 
first base in the expression vector for the authentic reverse transcrip- 
tase. Bases in bold face refer to the junction region where overhangs 
were filled in with Klenow polymerase. PL, X PI_ promoter; SD, 
Shine-Delgarno ribosome binding site; Amp’, ampicillin resistance 
gene; ori, origin of replication; Tet’, tetracyclin resistance gene. Fur- 
ther details are given in the section 2. (b) Amino acid sequence of the 
HIV-l RNase H domain. Tyr at position 427 is the first amino acid 
from the reverse transcriptase sequence. The arrows indicate the 
HIV-l protease processing sites observed in this study. 
the above components and aliquots from the reaction were removed 
at various times and spotted onto DEAE filters (Whatman DE81). 
After washing 3 x 15 min in 5% NazHP04 and drying, the amount 
of undigested RNA remaining on the filter was determined by scin- 
tillation counting. 
2.6. Analytical methods 
SDS/PAGE, isolectric focusing and N-terminal sequence analysis 
were all performed as previously described 1141. 
2.7. ‘H-NMR spectroscopy 
The sample for NMR spectroscopy contained 0.6 mM RNase H in 
50 mM sodium phosphate, pH 7.7 in 90% HzO/lO% DzO. The spec- 
trum was recorded on a Bruker AM600 600 MHz spectrometer at 
35°C and the water resonance was suppressed by low power coherent 
presaturation. Chemical shifts are expressed relative to 4,4-dimethyl- 
4-silapentane-1-sulfonate. 
2.8. Circular dichroic spectra 
Spectra were recorded on a Jasco J-600 spectropolarimeter. 
Measurements in the far ultraviolet region (180-240 nm) were made 
using a protein solution of 1 .O mg/ml, a 0.01 cm pathlength cell and 
1 nm bandwidth. Protein was buffered with 50 mM sodium 
phosphate, pH 7.5. The spectrum was the average of 4 scans with the 
base-line subtracted. The mean residue molecular mass was calculated 
as 110.3. Secondary structure content was estimated by the method of 
Provencher and Gloeckner [15]. 
2.9. HIV-Protease cleavage of RNase H domain 
The HIV-Protease was produced in E. co/i as a fusion product with 
a modified IgG binding domain derived from protein A and purified 
as described previously [16]. HIV-RNase H (2.3 mg/ml) was in- 
cubated with protease (0.15 mg/ml) in 50 mM sodium acetate, 0.1 
mM EDTA, 10% glycerol, 5vo ethylene glycol and 1 mM 
dithiothreitol pH 5.8, for 5 hat 37°C. The reaction was terminated by 
acidification with trifluroacetic acid. Products were separated on a 
Vydac Cl8 column run at 1 ml/min using a gradient from 0 to 70% 
acetonitrile in 0.05% trifluroacetic acid over 35 min (2%/min). A 
Tyr-containing peptide eluted with 35% acetonitrile, while a Trp con- 
a b C d 
_1 ^  
Fig. 2. SDS/PAGE of HIV-l RNase H. Lane (d), cell extract after 
centrifugation; lane(c), pooled fraction after DEAE-Sepharose stage; 
lane (b) purified protein: and lane (a) M, markers, the molecular 
masses of which are indicated in kDa. All samples were run on a 20% 
homogeneous Phast gel stained with Coomassie blue. 
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taining peptide eluted at 42% acetonitrile. Due to some impurities in 
the Trp containing peptide this was rerun with an acetonitrile gradient 
at 1 %/min. 
3. RESULTS AND DISCUSSION 
The strategy used in the construction of the vector for 
overproduction of the RNase H domain of HIV-l 
reverse transcriptase is summarized in Fig. 1. Using the 
host/vector system described, high level expression of 
the HIV RNase H domain was achieved. The protein 
constituted about 5-10070 of the soluble cytoplasmic E. 
coli proteins (Fig. 2, lane d). The protein was purified 
to homogeneity (Fig. 2, lane b) using a combination of 
ion-exchange and gel filtration chromatography. Small 
amounts of singly deaminated and dimerized protein 
were removed at the cation ion-exchange and the gel 
filtration stage, respectively. 1 g wet weight of E. coli 
cells yielded approximately 1.8 mg of purified protein. 
Assessment of enzymic activity during the purifica- 
tion was complicated by the presence of E. coli RNase 
H. This was especially problematic as the E. coli en- 
zyme exhibits a much higher specific activity than the 
RNase H activity associated with the HIV-reverse 
transcriptase (M. Krug and S. Berger, personal com- 
munication). RNase H activity was clearly detected up 
to the cation exchange chromatography stage but was 
not detected in subsequent stages. E. coli RNase H is 
predicted to be a basic protein (PI 8.7) and would, 
therefore, be expected to bind fairly tightly to the cation 
exchanger under the conditions used for the purifica- 
tion. The removal of RNase H activity at this stage is 
consistent with most of the measured activity being due 
to contaminating E. coli enzyme. Using modified con- 
ditions for the enzyme assay, the RNase H domain pro- 
tein appears to have some detectable, albeit, very low 
activity. This activity does not stem from trace amounts 
of contaminating E. coli RNase H on the basis of 
kinetic and stability measurements. This work will be 
described in detail elsewhere (M. Krug and S. Berger, 
personal communication). A possible cause for the low 
specific activity of the isolated HIV-l RNase H domain 
may be the requirement for the N-terminal 51 kDa por- 
tion of the reverse transcriptase for efficient binding of 
the substrate. Attempts to demonstrate substrate bin- 
6 porn 4 
Fig. 3. 600 MHz ‘H NMR spectrum of recombinant HIV-1 RNase H. The spectum was recorded at 35°C on a sample containing 0.6 mM protein 
in 50 mM sodium phosphate, pH 7.7 dissolved in 9O%H20/10% DzO. The upper trace shows the aromatic region of the spectrum plotted with 
a four-fold magnification. 
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ding to the HIV-l RNase H domain alone using U.V. 
induced cross linking have so far been unsuccessful (S. 
Stahl, unpublished results). 
The molecular mass estimated by SDS-PAGE (Fig. 2, 
lane b) is about 15 000, consistent with that predicted 
from the cDNA sequence (15 200). Under native condi- 
tions the protein appears to be monomeric as judged by 
gel filtration experiments (data not shown). The isoelec- 
tric point of the protein (pl - 5.3) is also close to that 
predicted from the cDNA sequence. The first cycle of 
N-terminal sequencing indicated that methionine, 
derived from initiating N-formyl methionine, had not 
been processed. This is not surprising as the second 
residue (Asn) has a relatively large radius of gyration 
[ 171. Further sequencing (19 cycles) confirmed the se- 
quence of the first 20 amino acid residues. 
Due to the detection of only very low levels of en- 
zymic activity, it was important to establish that the 
HIV RNase H domain protein had a stable folded three- 
dimensional structure and did not exhibit a random coil 
conformation. As is illustrated in Fig. 3 the protein 
gives rise to a ‘H NMR spectrum expected for a folded 
protein. This is evidenced by the excellent chemical shift 
dispersion, both for the amide proton region as well as 
for the aliphatic protons. In particular, it is likely that 
the protein contains a high amount of P-sheet structure 
as a large number of well resolved resonances just 
downfield of the water peak are visible between 5 and 6 
ppm. These commonly arise from downfield shifted 
C”H protons in P-sheets. 
Thus, it is clear that the purified protein has a com- 
pact and well defined tertiary structure. An estimate of 
the secondary structure using the far ultraviolet circular 
dichroic spectrum (Fig. 4) indicates a high P-sheet con- 
tent. The protein appears to contain 15-20% a-helix 
and 60-68% P-sheet. This is consistent with the ‘H 
NMR spectrum which was recorded at a lo-fold higher 
protein concentration. The far ultraviolet circular 
dichroic spectrum of the HIV-RNase H domain is 
qualitatively similar to that recently reported for the E. 
coli RNase H [18]. Similar to the HIV protein, the E. 
coli RNase H(M, = 18 000) exhibits a substantial p- 
sheet content (4lCro). The CD evidence combined with 
the known sequence similarities and conservation of 
critical residues adds further weight to the view that the 
main chain fold of these two proteins is similar. 
HIV-l reverse transcriptase is initially produced in 
virus infected cells as a polyprotein. Upon processing 
by the pol encoded viral protease, it is found as a 66 
kDa and a 51 kDa polypeptide which form a 
heterodimer [191. A similar p5 l/p66 heterodimer can be 
prepared from purified p66 reverse transcriptase by (Y- 
chymotrypsin cleavage [9]. As the coding sequence used 
in our construction of the RNase H domain encom- 
passes several amino acids preceding the proteolytic 
cleavage site around residues 430-440 of the HIV-l 
reverse transcriptase [9], we proceeded to use our 
0 
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Fig. 4. Far ultraviolet circular dichroic spectrum of HIV-l RNase H. 
The spectum was recorded at 25°C as described in section 2. The 
mean residue ellipticity 0 has the unit: deg . cm2 . dmol - I. 
purified domain as a substrate for the HIV protease. 
Treatment of the RNase H domain with purified HIV- 
protease generated two main peptides. A Tyr contain- 
ing peptide eluting at 35% acetonitrile had the N- 
terminal sequence: YVDGAANRETKLGK. This se- 
quence indicated cleavage between Phe-440 and 
Tyr-441 (Fig. lb). This result was corroborated whilst 
this paper was in preparation, when it was reported that 
in vitro HIV-protease cleavage of homodimeric 66 kDa 
HIV-l reverse transcriptase also results in C-terminal 
cleavage at Phe-440, generating a 66/51 kDa 
heterodimer [20]. 
A second minor Trp containing peptide was 
generated by protease treatment of the RNase H do- 
main protein (see Materials and Methods). N-terminal 
sequence analysis of this peptide revealed the following 
sequence: LAWVPAHKGIGGN. This result indicates 
protease cleavage between Tyr-532 and Leu-533 (Fig. 
lb). Processing of the reverse transcriptase at this site 
has not been previously reported. It is of interest to 
note, however, that a purified C-terminal deletion mu- 
tant of reverse transcriptase, terminating with Pro-537 
has no detectable RNase H activity, whereas reverse 
transcriptase activity is not affected (S. Stahl and P. 
Wingfield, unpublished data). 
4. CONCLUSIONS 
Using the methods described, large amounts of the 
reverse transcriptase RNase H domain can be produced 
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as a soluble monomeric protein in E. coli. The purified 
recombinant protein appears conformationally 
homogeneous and well suited for structural studies by 
NMR spectroscopy, as well as for crystallization at- 
tempts. The determination of the HIV-protease pro- 
cessing site will allow the production of a minimal 
length RNase H domain and this work is currently 
underway. 
Acknowledgemenrx We thank Dr. Joseph Shiloach for the bacterial 
fermentations and Dallas Lee for technical assistance. This work was 
supported by the Intramural AIDS Targeted Program of the Office of 
the Director of the National Institutes of Health. A.R.K. thanks the 
Swedish Medical Research Council for their support. 
REFERENCES 
111 
121 
131 
[41 
151 
PI 
[71 
Kotewicz, M.L., Sampson, C.M., d’Alessio, J.M. and Gerard, 
G.F. (1988) Nucleic Acids Res. 16, 265-277. 
Tanese, N. and Goff, S.P. (1988) Proc. Nat]. Acad. Sci. USA 
85, 1777-1781. 
Repaske, R., Hartley, J.W., Karlick, M.F., O’Neill, R.R. and 
Austin, J.B. (1989) J. Viral. 63, 1460-1465. 
Schatz, O., Cromme, F.V., Grtlninger-Leitch, F. and LeGrice, 
S.F.J. (1989) FEBS Lett. 257, 311-314. 
Krug, M.S. and Berger, S.L. (1989) Proc. Natl. Acad. Sci. USA 
86, 3539-3543. 
Schatz, O., Mous, J. and LeGrice, S.F. J. (1990) EMBO J. 9, 
1171-1176. 
Schatz, O., Cromme, F., Naas, T., Lindemann, D., Mous, J. 
and LeGrice, S.F.J. (1990) in: Gene Regulation and AIDS 
Papas, T.S. (ed.), Portfolio, Houston. 
PI 
[91 
[lOI 
illI 
WI 
1131 
1141 
1151 
1161 
1171 
[181 
[I91 
WI 
Johnson, M.S., McClure, M.A., Feng, D.-F., Gray, J. and 
Doolittle, R.F. (1986) Proc. Natl. Acad. Sci. USA 83, 
7648-7652. 
Lowe, D.M., Aitken, A., Bradley, C., Darby, G.K., Larder, 
B.A., Powell, K.L., Purifoy, D.J.M., Tisdale, M. and Stam- 
mers, D.K. (1988) Biochemistry 27, 8884-8889. 
Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, 
B., Josephs, S.F., Doran, E.R., Rafalski, J.A., Whitehorn, 
E.A., Baumeister, K., Ivanoff, L., Petteway, S.R., Pearson, 
M.L., Lautenberger, J.A., Papas, T.S., Ghrayeb, J., Chang, 
N.T., Gallo, R.C. and Wong-Staal, F. (1985) Nature 313, 
277-384. 
Crowl, R., Seamans, C., Lomedico, P. and McAndrew, S. 
(1985) Gene 38, 31-38. 
Allet, B., Payton, M., Mattaliano, R.J., Gronenborn, A.M., 
Clore, G.M. and Wingfield, P.T. (1988) Gene 65, 259-268. 
Crouch, R.J. (1974) J. Biol. Chem. 249, 1314-1316. 
Wingfield, P.T., Payton, M., Tavenier, J., Barnes, M., Shaw, 
A., Rose, K., Simona, M.G., Demczuck, S., Williamson, K. and 
Dayer, J.M. (1986) Eur. J. Biochem. 160, 491-497. 
Provencher, S.W. and Gloeckner, J. (1981) Biochemistry 20, 
33-37. 
Boutelje, J., Karlstrom, A.R., Hartmanis, M.G.N., Holmgren, 
E., Sjogren, A. and Levine, R.L. (1990) Arch. Biochem. 
Biophys. (in press). 
Serman, F., Steward, J.W. and Tsunassasawa, S. (1985) 
Bioassays 3, 27-3 1. 
Kanaya, S., Kohara, A., Miura, Y., Sekiguchi, A., Iwai, S., In- 
oue, H., Ohtsuka, E. and Ikehara, M. (1990) J. Biol. Chem. 265, 
4615-4621. 
Di Marzo Veronese, F., Copeland, T.D., DeVico, A.L., 
Rahman, R., Oroszlan, S., Gallo, R.C. and Sarngadharan, 
M.G. (1986) Science 231, 1289-1291. 
Graves, M.C., Meidel, M.C., Pan, Y.-C.E., Manneberg, M., 
Lahm, H.-W. and Grilninger-Leitch, F. (1990) Biochem. 
Biophys. Res. Comm. 168, 30-36. 
80 
